Table 1

ReferenceAgeM/FHb (g/L)Platelets (×109/L)Plasma-pheresisHematological diagnosisChemotherapy 1st lineSubsequent chemotherapyApproximate survival from the beginning of the first therapy for hemolysis (if applicable) or presentation

[9]70M7280YesTTPCarboplatin/paclitaxel14 days
[10]52F7262NoMAHANone1 week
[10]28M7577NoMAHANone1 week
[10]21M61342NoMAHANone1 week
[8]62M10786NoMAHAEtoposide 120 mg/m2, leucovorin 300 mg/m2, and 5-FU 500 mg/m2 days 1–3, every 21 days5-FU 2000 mg/m2, leucovorin 500 mg/m2, oxaliplatin 130 mg/m2 day 1 every 14 days12 months
[11]19M10098NoMAHA with DIC 5-FU, adriamycin, and mitomycin-C6 days
[12]61F 95 estNRNoCancer-related thrombotic microangiopathyInfusional 5-FU 250 mg/m2/day35 days
[13]60M8243YesTTP5-FU, adriamycin, and mitomycin C 6 months
[14]59F6120YesTTPNone1 month
[14]65F8086NoTTPPaclitaxel11 months
[15]52M6024YesMAHA without DICNone4 weeks
[16]75M81NRNoMAHANone20 days
[17]58F5814NoMAHA5-FU, vincristine, methotrexate, and cyclophosphamide10 days
[18]50M7350YesCancer-associated MAHADocetaxel, 5-FU, and platinum12 days
[4]71M4418NoTTPNoneCurative-intent surgery
[19]25F74100NoMAHA5-FU 600 mg/m2 weekly + adriamycin 40 mg/m2 day 1, q21 daysMitomycin-C 10 mg/m2 monthly7 months
[20]28F52111YesTTPCisplatin/5-FU infusionUnder 2 months
[7]45M5950NoMAHA and thrombocytopeniaCisplatin 60 mg/m2 day 1, 5-FU 600 mg/m2/day infusion days 1–4, every 21 days7 weeks
[7]32FNRNRYesMAHA and thrombocytopeniaCisplatin 20 mg/m2 days 1–5, etoposide 60 mg/m2 days 1–5, every 21 days5-FU 298 (=70% of 425) mg/m2 and leucovorin 20 mg/m2 days 1–5, and weekly cetuximab 500 mg IV, all every 21 days12 weeks approx..
[5]71F5615.6NoMAHAMitomycin-C 10 mg and neothramycin (also gabexate infusion), 5 doses over 2 months3 months
[6]69M6564YesThrombotic microangiopathy with renal failureN/ACurative intent surgery
[21]60M9835NoDICNone24 days
[22]83F4085NoMHANone3 days
[23]47F499NoMAHACisplatin 80 mg/m2 day 1, 5-FU 1000 mg/m2/day, days 1–5FOLFIRI, DCF at 20% dose reduction19 months
[24]69F96104NoMAHAAdriamycin4 weeks
[25]44M7471NoMAHA and DICNone3 months
[26]57M5839NoDICMethotrexate 100 mg/m2 day 1, 5-FU bolus 600 mg/m2 day 1, LV 10 mg/m2 q6h days 2 and 3, weekly10 months
[27]52F6818NoThrombotic microangiopathy 5-FU, cisplatin, and hydroxyurea3 months
[27]51M7474NoThrombotic microangiopathy Gemcitabine, oxaliplatin, irinotecan, 5-FU, and docetaxel (details not reported)4 months
[27]59M6639YesThrombotic microangiopathy None44 days
[28]51F6740YesTTPVincristine 2 mgCisplatin 50 mg/m2days 1 + 15, 5-FU 150 mg/m2, and LV 500 mg weekly3 months
[29]59F8623NoDICNone10 days
[29]51F39120NoDICNone22 days
[29]46F11559NoDICNone8 days
[30]43M53NRNoHUSNoneSurgery, no recurrence
[31]66M70250NoMAHA5-FU 425 mg/m2 and leucovorin 20 mg/m2 daily 5-FU 425 mg/m2 and leucovorin 20 mg/m2 daily 26 months
[32]NRNR4345NoMAHACisplatin/5-FU 2 days
[33]50M8595NoPulmonary tumour Thrombotic microangiopathy5-FU 250 mg daily, mitomycin C 7 mg weekly, and cisplatin 125 mg once86 days
[34]66M7328NoHemol. anemiaNone15 days
[34]43M9150Hemol. anemiaNone7 days
[35]43M7862NoDIC/MAHAMMC, 5-FU, Ara-C, and heparin6 months
[36]27F7223YesThrombotic microangiopathyNone3 days
Our case49M5276YesCR-MAHACisplatin 50 mg/m2 day 1, 5-FU infusion 1000 mg/m2/day, days 1 through 4, all every 21 days Docetaxel 25 mg/m2 weekly, cisplatin 60 mg/m2 every 21 days, and 200 mg/m2 5-FU infusion daily16 months

CR: cancer-related; DIC: disseminated intravascular coagulation; 5-FU: 5-fluorouracil; HUS: hemolytic uremic syndrome; MAHA: microangiopathic hemolytic anemia; MMC: mitomycin-C; TTP: thrombotic thrombocytopenic purpura.